StemCell Therapy

Actus Therapeutics Inc.

Actus Therapeutics develops gene therapies for rare diseases including Pompe disease and epilepsy.

Adrenas Therapeutics is developing a gene therapy for the treatment of a monogenic disease that presents in childhood.

Asklepios BioPharmaceutical (AskBio) develops protein- and cell-based therapies using a proprietary technology platform called Biological Nano Particles (BNP).

The Division of Therapeutic Research and Development at Atrium Health conducts clinical studies, patient-focused translational research and outcomes research.

AveXis develops and commercializes gene therapy products for neurological genetic diseases. The Durham site is AveXis' manufacturing operations.

Couragen Biopharmaceutics develops gene and protein therapy products for preclinical and clinical use for the treatment of genetic and chronic diseases. Couragen also provides custom adeno-associated virus vectors as a tool for laboratory research.

Elo Life Systems develops Precision Biosciences' technology, called Directed Nuclease Editor, to site-specifically insert or remove traits at a user-defined location in the genome of row crops, biofuel feedstocks and other plants.

Enzerna Biosciences is developing molecular tools for reversible, precise manipulation of gene expression, using technologies that create sequence-specific RNA binding proteins. Enzerna also offers mitochondrial toxicity models and testing.

Falcon Therapeutics is developing personalized neural stem cell therapies to treat cancers.

Fujifilm Diosynth Biotechnologies provides biologics contract development and manufacturing. Services include cell line development, process and analytical development, clinical and commercial manufacturing and bioprocess research and development.

Gene Facelift develops a cosmetic gene therapy in a topical cream formulation to reduce wrinkles, regenerate collagen and restore aging skin. The delivery platform will be used to develop wound healing drugs.

Gyrus Pharmaceuticals is developing treatments for serious diseases of the central nervous system using proprietary therapeutic agents and nanoparticles for noninvasive delivery to the CNS.

NanoCor Therapeutics develops an intracellular genetic protein therapy for the treatment of chronic heart failure.

The NCSU Technology Incubator at Centennial Campus offers a program and facilities specifically designed for tech start-ups with high-impact potential.

Ocis Biotechnology develops implantable custom hydrogel medical devices for surgical implantation and injection that produce time-released biologics for tissue regeneration.

Pfizer's Bamboo Therapeutics develops gene therapies to treat rare genetic central nervous system (CNS) and neuromuscular diseases, including Giant Axonal Neuropathy (GAN), Canavan Disease, Friedreich's Ataxia and Duchenne Muscular Dystrophy (DMD).

Precision BioSciences utilizes a proprietary genome editing method called ARCUS to treat cancers and genetic diseases, and enable the development of safer, more productive food sources.

Rescindo Therapeutics discovers novel therapeutic targets and drugs for human genetic disorders based on humanized zebrafish in vivo modeling.

StrideBio develops engineered viral vectors for gene therapy for the treatment of rare diseases. StrideBio's technology engine utilizes structure-inspired design to engineer AAV vectors which can escape pre-existing neutralizing antibodies (NAbs).

See original here:
Gene Therapy | North Carolina Biotech Center

This entry was posted on April 17, 2019 at 10:49 pm and is filed under Gene therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |